Key Considerations When Choosing an IRT System for Clinical Trials

By John Ristuccia, Sr. Vice President, Global Client Services Delivery

Choosing the right Interactive Response Technology (IRT) system is a critical decision for sponsors in clinical trials. When evaluating potential solutions, it is helpful to take into account three vital aspects: technology, process, and people. While technology is an obvious consideration, the people and processes involved are equally important, especially in complex and critical studies.  


Clinical trials, particularly in complex therapeutic areas like oncology, central nervous system, and rare disease, present unique challenges that demand a deep understanding of specific protocols and associated system modules. An effective IRT system should be supported by a team that comprehends the intricacies of these protocols and can swiftly handle mid-trial amendments and issues. That’s why it is crucial to partner with an IRT system provider that has an in-depth understanding of complex clinical protocols and associated system modules to get tailored solutions that align with trial objectives. 

An experienced IRT support team familiar with the science and technology driving your trial can also significantly enhance its chances of success. With 70% of Suvoda’s clinical trials relating to complex therapeutic areas of oncology, central nervous system, and rare disease, all of Suvoda’s IRT services teams are experienced in complex trials. This expertise, combined with a fully customizable IRT that’s unified on a single platform with eCOA and eConsent, can help sponsors execute successful studies. 



John Ristuccia
Sr. Vice President, Global Client Services Delivery

More from John Ristuccia

4 Reasons Superior IRT Service Matters

3 ways flexible technology supports the complexity of rare disease trials